Background: The prognostic value of hs-CRP in patients with congestive heart failure(CHF) has not yet been thoroughly assessed. Thus, we evaluated the prognostic value of hs-CRP in this population. Method: From January to July 2004, serum hs-CRP and NT-proBNP levels were measured in 81 patients with symptoms of CHF and LVEF< 50%. Patients with acute myocardial infarction were excluded. Major adverse cardiac events(death, readmission, non-fatal CVD) during 1 year follow-up were reviewed. Prognostic values of hs-CRP and NT-proBNP were analyzed. Results: MACE's occurred in 46.9% of the patients(death:15, readmission:22, non-fatal CVD:1). The serum levels of hs-CRP(p=0.014) and NT-proBNP(p=0.000) were significantly increased in patients with MACE's. In a multiple logistic regression analysis, hs-CRP(p=0.048) and NT-proBNP(p=0.009) were independent predictors for MACE's. To analyze the cummulative prognostic significance of hs-CRP and NT-proBNP on mortality, we divided 81 patients into three groups(group I: hs-CRP <5mg/L and NT-proBNP <9000pg/mL, group 2: hs-CRP ���5mg/L or NT-proBNP ���9000pg/mL, group 3: hs-CRP ���5mg/L and NT-proBNP ���9000pg/mL). The mortality was elevated in group 2(N=34, odds ratio=2.17) and group 3(N=19, odds ratio=9.76) than group 1(N=28) by Cox regression analysis(p=0.013). Conclusion: These findings suggest hs-CRP and NT-proBNP are independent predictors of prognosis in CHF and the number of elevated biomarkers can provide additional prognostic information for the risk stratification in patients with CHF.